Gilead’s pill posts stronger colitis remission rates than Entyvio

Phase 2positiveoral α4β7 inhibitorPositive

AI Analysis

Summary

Gilead Sciences reported Phase 2 dose-finding data for its oral α4β7 inhibitor in ulcerative colitis, suggesting stronger remission rates than rival products including Entyvio. The company plans to begin late-stage trials next year.

Clinical Trial Data

Phase

Phase_2

Outcome Details

Phase 2 dose-finding trial suggested stronger colitis remission rates than rival Entyvio (vedolizumab); Gilead plans to start late-stage trials next year.

Importance:7/10

Sentiment:

0.60

ulcerative colitisoralα4β7 inhibitorPhase 2Entyvioinflammatory bowel disease

Related Companies

$GILD

Read the original article

Published by Endpoints News on October 19, 2026 3:05 PM

Read Original